Last reviewed · How we verify
NCT00902369
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
Phase 2 trial testing AK106-001616 in Rheumatoid Arthritis in 130 participants. Completed in 1 July 2010.
1 October 2009
Quick facts
| Lead sponsor | Asahi Kasei Therapeutics Corporation |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 130 |
| Start date | 1 May 2009 |
| Primary completion | 1 October 2009 |
| Estimated completion | 1 July 2010 |
| Sites | 12 locations across Czechia, Germany, Hungary, Lithuania, Romania, United Kingdom |
Drugs / interventions tested
- AK106-001616 — full drug profile →
- Placebo
- Active comparator — full drug profile →
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
Asahi Kasei Therapeutics Corporation
Who can join
Adults 18 to 65, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This will be a Phase II, multi-centre study consisting of 2 parts. Part 1: Clinical Pharmacology Study (drug-drug interaction between AK106-001616 and methotrexate) Part 2: Proof of Concept Study
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients.
Kozaki T, Tagashira M, Yamanishi K, Ellis B, et al · · 2015 · cited 8× · PMID 25579091 · DOI 10.3109/00498254.2014.1000430
Verify or expand the search:
- PubMed search for NCT00902369
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other Asahi Kasei Therapeutics Corporation trials
Trials by the same sponsor.
- NCT05227677 — Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes · NA · completed
- NCT04483297 — First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) · Phase 1 · terminated
- NCT03471988 — Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00902369 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asahi Kasei Therapeutics Corporation
- Last refreshed: 21 July 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00902369.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing